Global CAR-T Therapy for Hematological Cancer Market Growth (Status and Outlook) 2024-2030

The global CAR-T Therapy for Hematological Cancer market size is predicted to grow from US$ 5299 million in 2024 to US$ 22200 million in 2030; it is expected to grow at a CAGR of 27.0% from 2024 to 2030.

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a cutting-edge immunotherapy for hematological cancers, involving the genetic modification of a patient’s T cells to express synthetic receptors targeting specific antigens on cancer cells. These engineered T cells are expanded in the lab and reintroduced into the patient, where they can recognize and destroy cancerous cells with high specificity. Key features include its remarkable efficacy in treating certain blood cancers like B-cell lymphomas, leukemias, and multiple myeloma, particularly in patients with relapsed or refractory disease, and its potential for long-term remission. CAR-T therapy is primarily applied in advanced hematological malignancies and is being explored for broader indications through ongoing clinical trials. Despite its promise, challenges such as high cost, manufacturing complexity, and management of severe side effects like cytokine release syndrome (CRS) remain areas of active research.

United States market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for CAR-T Therapy for Hematological Cancer is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key CAR-T Therapy for Hematological Cancer players cover Novartis, Gilead Sciences, Bristol-Myers Squibb, J&J, JW Therapeutics, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

LPI (LP Information)' newest research report, the “CAR-T Therapy for Hematological Cancer Industry Forecast” looks at past sales and reviews total world CAR-T Therapy for Hematological Cancer sales in 2023, providing a comprehensive analysis by region and market sector of projected CAR-T Therapy for Hematological Cancer sales for 2024 through 2030. With CAR-T Therapy for Hematological Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR-T Therapy for Hematological Cancer industry.

This Insight Report provides a comprehensive analysis of the global CAR-T Therapy for Hematological Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR-T Therapy for Hematological Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR-T Therapy for Hematological Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR-T Therapy for Hematological Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR-T Therapy for Hematological Cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR-T Therapy for Hematological Cancer market by product type, application, key players and key regions and countries.

Segmentation by Type:
Target: CD19
Target: BCMA
Others

Segmentation by Application:
Lymphoma
Multiple Myeloma
Leukemia

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J&J
JW Therapeutics
FOSUNKite

Please note: The report will take approximately 2 business days to prepare and deliver.